A study to find out what happens to a new medicine (inavolisib) inside the human body
Cancer Breast Cancer Breast Cancer HER-2 Positive
Basic Details
Eight healthy volunteers were enrolled at one study site in USA to evaluate the bioavailability, metabolism, and excretion of inavolisib, a small molecule inhibitor of the Class I PI3Kα isoform and with increased potency in PI3K with mutated p110α. All 8 participants completed the study. Results showed inavolisib was removed from the body through passing urine and feces, and the bioavailability of the oral capsule was 76%. There were no deaths or serious AEs. The data from this study will help support further development of inavolisib.
The source of the below information is public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc.. It has been summarised and edited into simpler language. For more information about this clinical study see the For Expert tab on the specific ForPatients page or follow these links to https://clinicaltrials.gov and/or https://euclinicaltrials.eu and/or https://www.isrctn.com.
The information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc., and has not been edited.
Results Disclaimer
For the latest version of this information please go to www.forpatients.roche.com